These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31138731)
21. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pedersen S; Warner J; Wahn U; Staab D; Le Bourgeois M; Van Essen-Zandvliet E; Arora S; Szefler SJ; Pediatrics; 2002 Jun; 109(6):e92. PubMed ID: 12042586 [TBL] [Abstract][Full Text] [Related]
22. Respiratory Tract Deposition of HFA-Beclomethasone and HFA-Fluticasone in Asthmatic Patients. Leach CL; Kuehl PJ; Chand R; McDonald JD J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):127-33. PubMed ID: 26061801 [TBL] [Abstract][Full Text] [Related]
23. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Agertoft L; Laulund LW; Harrison LI; Pedersen S Pediatr Pulmonol; 2003 Mar; 35(3):192-9. PubMed ID: 12567387 [TBL] [Abstract][Full Text] [Related]
24. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. Leach CL; Davidson PJ; Hasselquist BE; Boudreau RJ Chest; 2002 Aug; 122(2):510-6. PubMed ID: 12171824 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (Part 2): Clinical experience in children. van Schayck CP; Donnell D Int J Clin Pract; 2004 Aug; 58(8):786-94. PubMed ID: 15372852 [TBL] [Abstract][Full Text] [Related]
26. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Singh D; Collarini S; Poli G; Acerbi D; Amadasi A; Rusca A Br J Clin Pharmacol; 2011 Dec; 72(6):932-9. PubMed ID: 21615456 [TBL] [Abstract][Full Text] [Related]
27. The delivery of chlorofluorocarbon-propelled versus hydrofluoroalkane-propelled beclomethasone dipropionate aerosol to the mechanically ventilated patient: a laboratory study. Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC; Migounov VA Respir Care; 2003 Nov; 48(11):1025-32. PubMed ID: 14585114 [TBL] [Abstract][Full Text] [Related]
29. In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs. Shemirani FM; Hoe S; Lewis D; Church T; Vehring R; Finlay WH J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):215-22. PubMed ID: 23094687 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma. Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292 [TBL] [Abstract][Full Text] [Related]
31. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma. Bulac S; Cimrin A; Ellidokuz H J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594 [TBL] [Abstract][Full Text] [Related]
32. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122 [TBL] [Abstract][Full Text] [Related]
33. Both bronchial and alveolar exhaled nitric oxide are reduced with extrafine beclomethasone dipropionate in asthma. Nicolini G; Chetta A; Simonazzi A; Tzani P; Aiello M; Olivieri D Allergy Asthma Proc; 2010; 31(5):85-90. PubMed ID: 20929599 [TBL] [Abstract][Full Text] [Related]
34. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination. Bousquet J; Poli G; Acerbi D; Monno R; Ramael S; Nollevaux F Clin Pharmacokinet; 2009; 48(6):347-58. PubMed ID: 19650674 [TBL] [Abstract][Full Text] [Related]
36. Systemic activity of inhaled beclomethasone dipropionate: a double-blind comparison of volume spacers. Wolthers OD; Sergio F Acta Paediatr; 2012 Feb; 101(2):159-63. PubMed ID: 21790779 [TBL] [Abstract][Full Text] [Related]
37. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort Gillen M; Forte P; Svensson JO; Lamarca R; Burke J; Rask K; Larsdotter Nilsson U; Eckerwall G Pulm Pharmacol Ther; 2018 Oct; 52():7-17. PubMed ID: 30077809 [TBL] [Abstract][Full Text] [Related]
38. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. Micheletto C; Guerriero M; Tognella S; Dal Negro RW Respir Med; 2005 Jul; 99(7):850-5. PubMed ID: 15939246 [TBL] [Abstract][Full Text] [Related]
39. Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Milanowski J; Qualtrough J; Perrin VL Respir Med; 1999 Apr; 93(4):245-51. PubMed ID: 10464888 [TBL] [Abstract][Full Text] [Related]
40. Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment. Wolthers OD; Moore A; Mersmann S; Dissanayake S J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):373-380. PubMed ID: 28510491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]